Tenaya Therapeutics does not distribute cash dividends to its common shareholders, maintaining a dividend yield of zero percent. As a clinical-stage biopharmaceutical enterprise focused on intensive research, laboratory development, and clinical trials for cardiovascular diseases, the company preserves all available capital to fund ongoing scientific operations rather than issuing cash payouts.